MDGL

434.24

4.21% -19.10

시간 외 거래: 434.24

Madrigal Pharmaceuticals Inc (MDGL)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측 주식 분할

전일 마감가:

$453.34

열려 있는:

$453.55

하루 거래량:

234.84K

Relative Volume:

0.73

시가총액:

$10.03B

수익:

$1.13B

순이익/손실:

$-309.44M

주가수익비율:

-33.92

EPS:

-12.8001

순현금흐름:

$-275.41M

1주 성능:

-3.45%

1개월 성능:

-15.36%

6개월 성능:

-16.29%

1년 성능:

+2.45%

1일 변동 폭

$433.31

$453.55

1주일 범위

$433.31

$481.87

52주 변동 폭

$393.61

$615.00

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

명칭

Madrigal Pharmaceuticals Inc

부문

Healthcare (1052)

산업

Biotechnology (594)

전화

404-380-9263

주소

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

직원

915

트위터

@MadrigalPharma

다음 수익 날짜

2026-11-03

최신 SEC 제출 서류

MDGL's Discussions on Twitter

Compare MDGL vs VRTX, REGN, MRNA, ARGX, ONC

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
MDGL Madrigal Pharmaceuticals Inc	434.24	10.03B	1.13B	-309.44M	-275.41M	-12.80
VRTX Vertex Pharmaceuticals Inc	523.93	132.80B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.02	82.88B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	200.10	79.89B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	873.71	54.94B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	377.63	42.72B	5.76B	514.49M	1.10B	4.4813

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2026-09-24	재개	Goldman	Buy
2026-09-23	개시	Citigroup	Buy
2026-08-04	업그레이드	Wolfe Research	Peer Perform → Outperform
2026-07-27	개시	Wells Fargo	Overweight
2026-01-28	개시	Barclays	Overweight
2026-01-06	다운그레이드	Wolfe Research	Outperform → Peer Perform
2025-11-05	업그레이드	Cantor Fitzgerald	Neutral → Overweight
2025-11-03	업그레이드	BofA Securities	Underperform → Neutral
2025-10-15	개시	Truist	Buy
2025-09-04	재개	H.C. Wainwright	Buy
2025-02-28	업그레이드	B. Riley Securities	Neutral → Buy
2025-02-27	재확인	H.C. Wainwright	Buy
2024-06-28	개시	Cantor Fitzgerald	Neutral
2024-06-11	개시	Wolfe Research	Outperform
2024-04-22	개시	BofA Securities	Underperform
2024-03-15	업그레이드	B. Riley Securities	Sell → Neutral
2024-03-06	개시	Citigroup	Buy
2024-02-26	다운그레이드	B. Riley Securities	Neutral → Sell
2022-12-20	재확인	Oppenheimer	Outperform
2022-12-19	재확인	H.C. Wainwright	Buy
2022-12-19	재확인	Piper Sandler	Overweight
2022-12-19	업그레이드	Raymond James	Underperform → Mkt Perform
2022-07-08	다운그레이드	B. Riley Securities	Buy → Neutral
2021-10-07	개시	Jefferies	Buy
2021-08-06	업그레이드	BMO Capital Markets	Market Perform → Outperform
2021-05-20	재개	Goldman	Buy
2020-11-24	재개	Evercore ISI	Outperform
2020-11-06	재확인	H.C. Wainwright	Buy
2020-07-31	개시	Piper Sandler	Overweight
2020-06-05	개시	BMO Capital Markets	Market Perform
2020-05-05	개시	Chardan Capital Markets	Buy
2020-01-30	개시	Canaccord Genuity	Buy
2020-01-09	업그레이드	UBS	Neutral → Buy
2019-11-07	재확인	H.C. Wainwright	Buy
2019-06-25	개시	Stifel	Hold
2019-06-10	업그레이드	B. Riley FBR	Neutral → Buy
2019-02-28	재확인	H.C. Wainwright	Buy
2019-02-22	개시	SVB Leerink	Outperform
2019-01-23	개시	UBS	Neutral
2018-12-14	개시	Wolfe Research	Outperform
2018-12-12	개시	B. Riley FBR	Neutral
2018-11-19	다운그레이드	Raymond James	Mkt Perform → Underperform
2018-11-16	업그레이드	Evercore ISI	In-line → Outperform
2018-09-04	개시	Citigroup	Buy
2018-08-06	다운그레이드	Goldman	Buy → Neutral
2018-06-28	개시	Raymond James	Mkt Perform

모두보기

Madrigal Pharmaceuticals Inc 주식(MDGL)의 최신 뉴스

Oct 20, 2026

Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight - GlobeNewswire Inc.

Oct 20, 2026

Oct 19, 2026

symbol__ Stock Quote Price and Forecast - CNN

Oct 19, 2026

Oct 15, 2026

Stock awards for 26 new hires vest in four yearly installments at Madrigal - Stock Titan

Oct 15, 2026

Oct 08, 2026

Madrigal Pharmaceuticals (MDGL) Genetics Update Keeps Fair Value In Focus - Yahoo Finance

Oct 08, 2026

Oct 07, 2026

Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care? - Zacks Investment Research

Oct 07, 2026

Madrigal Pharmaceuticals stock gets fresh Rezdiffra data - AD HOC NEWS

Oct 07, 2026

Oct 06, 2026

A liver drug improved disease measures across several genetic risk groups - Stock Titan

Oct 06, 2026

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants - Yahoo Finance

Oct 06, 2026

Sep 28, 2026

Under an automatic trading plan, director Paul Friedman proposes to sell shares in Madrigal Pharmaceuticals (MDGL). - Stock Titan

Sep 28, 2026

Sep 21, 2026

Madrigal Grants Equity Awards to 27 New Employees - MyChesCo

Sep 21, 2026

Sep 16, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 16, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Sep 16, 2026

Sep 14, 2026

Have Insiders Sold Madrigal Pharmaceuticals Shares Recently? - Simply Wall Street

Sep 14, 2026

Sep 11, 2026

Understanding Momentum Shifts in (MDGL) - Stock Traders Daily

Sep 11, 2026

Madrigal Pharmaceuticals (NASDAQ: MDGL) insider plans another stock sale after recent multimillion-dollar trades - stocktitan.net

Sep 11, 2026

Madrigal Pharma CEO William John Sibold disposes of common shares worth $4.16 million - Bitget

Sep 11, 2026

Sep 10, 2026

Madrigal Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq

Sep 10, 2026

Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com Nigeria

Sep 10, 2026

Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com Canada

Sep 10, 2026

Madrigal at cantor healthcare conference: growth, access and pipeline - investing.com

Sep 10, 2026

Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com UK

Sep 10, 2026

Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? - Yahoo Finance

Sep 10, 2026

Madrigal Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq

Sep 10, 2026

Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? - The Motley Fool

Sep 10, 2026

Sep 09, 2026

Madrigal Pharmaceuticals (NASDAQ: MDGL) exec plans $3.4M stock sale for tax withholding - stocktitan.net

Sep 09, 2026

Sep 07, 2026

September 2026 Nasdaq Stock Market Bell Ceremonies - Nasdaq

Sep 07, 2026

Madrigal Pharmaceuticals (MDGL) Stock Analysis: A 25% Upside Potential In Biotech Innovation - DirectorsTalk Interviews

Sep 07, 2026

Sep 06, 2026

Madrigal to Put MASH Drug Strategy Before Investors at Cantor - MyChesCo

Sep 06, 2026

Sep 02, 2026

Madrigal Pharmaceuticals (MDGL) Leads Healthcare CapEx Growth Am - GuruFocus

Sep 02, 2026

Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - manilatimes.net

Sep 02, 2026

Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire

Sep 02, 2026

Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance

Sep 02, 2026

Aug 31, 2026